Open Access

Effects of lornoxicam on the physiology of severe sepsis

  • Dilek Memiş1Email author,
  • Beyhan Karamanlıoğlu2,
  • Alparslan Turan1,
  • Onur Koyuncu1 and
  • Zafer Pamukçu2
Critical Care20048:R474

https://doi.org/10.1186/cc2969

Received: 1 March 2004

Accepted: 2 September 2004

Published: 27 October 2004

Abstract

Introduction

The purpose of the present study was to evaluate the effects of intravenous lornoxicam on haemodynamic and biochemical parameters, serum cytokine levels and patient outcomes in severe sepsis.

Methods

A total of 40 patients with severe sepsis were included, and were randomly assigned (20 per group) to receive either lornoxicam (8 mg administered intravenously every 12 hours for six doses) or placebo. For both groups the following were recorded: haemodynamic parameters (heart rate, mean arterial pressure), nasopharyngeal body temperature, arterial blood gas changes (pH, partial oxygen tension, partial carbon dioxide tension), plasma cytokine levels (IL-1β, IL-2 receptor, IL-6, IL-8, tumour necrosis factor-α), biochemical parameters (lactate, leucocytes, trombocytes, creatinine, total bilirubin, serum glutamate oxalate transaminase), length of stay in the intensive care unit, duration of mechanical ventilation and mortality. All measurements were obtained at baseline (before the start of the study) and at 24, 48 and 72 hours from the start of lornoxicam/placebo administration.

Results

No significant differences were found between the intravenous lornoxicam and placebo groups in major cytokines, duration of ventilation and length of intensive care unit stay, and inspired fractional oxygen/arterial oxygen tension ratio (P > 0.05).

Conclusion

In these patients with severe sepsis, we found intravenous lornoxicam to exert no effect on haemodynamic and biochemical parameters, cytokine levels, or patient outcomes. Because of the small number of patients included in the study and the short period of observation, these findings require confirmation by larger clinical trials of intravenous lornoxicam, administered in a dose titrated manner.

Keywords

biochemical parameterscytokine levelshaemodynamic parametersintensive care unitlornoxicamoutcomesevere sepsis

Introduction

Sepsis is defined as the systemic response to infection [1, 2]. The deleterious effects of bacterial invasion of body tissues results from the combined actions of enzymes and toxins produced by the micro-organisms themselves, and the actions of endogenous cells in response to the infectious process. Despite advances in supportive care, mortality rates in patients with severe sepsis continue to exceed 30%. During sepsis vasoactive arachidonic acid metabolites of the cyclo-oxygenase (COX) pathway are released. In particular, thromboxane A2 and prostacyclin have been found to be elevated in sepsis [3, 4]. Thromboxane A2 has been associated with bronchoconstriction, vasocontriction and platelet aggregation [3]. Prostacyclin, the predominant eicosanoid generated by activated endothelial cells, is a powerful vasodilator and antagonist of thrombosis [3]. Prostaglandin (PG)E2 is among the most potent and inducible of the prostanoids that are produced in states of inflammation. Specifically, there is evidence to support roles for PGE2 as a mediator of sepsis-induced immunosuppression, an inhibitor of proinflammatory cytokine expression from monocytes, and an inducer of IL-10 production [57]. Conversely, PGE2 has been shown to mediate detrimental effects in sepsis, including vasodilation and increased vascular permeability [8]. In addition, its role as a mediator in fever induction and augmentation of pain is well established [9]. Several studies [1012] conducted in endotoxin-challenged animals have found beneficial effects of nonselective COX inhibitors. These beneficial effects were felt to be mediated, in part, by mitigation of pathophysiological events in sepsis induced by PGs.

COX exists as two isoforms – COX-1 and COX-2. The former is constitutively expressed, whereas COX-2 is expressed at low levels in most normal resting cells. Marked upregulation of COX-2 occurs in synoviocytes, macrophages and endothelial cells during stress and in inflammatory conditions such as sepsis. COX-2 expression is induced by a number of cytokines, including tumour necrosis factor (TNF) and IL-1, mitogens and growth factors, lipopolysaccharide (LPS), and other inflammatory stimuli [13]. Recent studies [14, 15] provided evidence suggesting that selective COX-2 inhibitors have significant advantages over their nonselective counterparts. The specific benefits of COX-2 inhibitors include decreased gastrointestinal toxicity and bleeding [14, 16].

As with other nonsteroidal anti-inflammatory drugs (NSAIDs), lornoxicam inhibits PG synthesis via inhibition of COX, but it does not inhibit 5-lipoxygenase. The ratio of inhibitory potency of human COX-1 to COX-2 for lornoxicam is 0.6 [17]. Lornoxicam was reported to be 100-fold more potent than tenoxicam in inhibiting PGD2 formation in rat polymorphonuclear leucocytes in vitro, and it was more active than indomethacin and piroxicam in preventing arachidonic acid induced lethality in mice in vivo [17]. Lornoxicam also inhibited the formation of nitric oxide in RAW264.7 mouse macrophages stimulated with endotoxin, indicating an effect on inducible nitric oxide synthase [18]. It also exhibited marked inhibitory properties on endotoxin-induced IL-6 formation in THP1 monocytes, with less activity on TNF and IL-1β. It appears that lornoxicam, in addition to markedly inhibiting COX and inducible nitric oxide synthase, has a moderate effect on the formation of proinflammatory cytokines [19].

The purpose of the present study was to evaluate the effects of intravenous lornoxicam on serum cytokine levels, haemodynamic and biochemical parameters, and outcomes in humans with severe sepsis.

Methods

Patient population and study design

The regional committee on medical research ethics approved the study. Written informed consent was obtained, directly from the patients wherever possible or from the next of kin. Critically ill patients with bacteriologically documented infections were included in the study as soon as they met at least two of the following criteria for sepsis, as defined by the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee [2]: temperature >38°C or <36°C; heart rate >90 beats/min; respiratory rate >20 breaths/min or arterial carbon dioxide tension <32 mmHg; and leucocyte count >12 × 109 cells/l or <4 × 109 cells/l. In addition, at least one of following conditions was required: hypoxaemia (arterial oxygen tension/fractional inspired oxygen ratio <250); oliguria (urine output <0.5 ml/kg body weight for 2 hours); lactic acidosis (lactate concentration >2 mmol/l); thrombocytopaenia (platelet count <100 × 109/l); and a recent change in mental status without sedation. Patients who were younger than 18 years, had known or suspected hypersensitivity to COX inhibitors, or had received a COX inhibitor within 12 hours (or aspirin within 24 hours) were enrolled in another experimental protocol (not part of the present study), or were excluded if consent could not be obtained. Also excluded were patients with known or suspected brain death; those with advanced acute or chronic renal or hepatic failure; those who had received potent immunosuppressive drugs; those with gastrointestinal bleeding; those who were pregnant; and those with a known irreversible underlying disease, such as end-stage neoplasm.

The Acute Physiology and Chronic Health Evaluation (APACHE) II score [20] and Sepsis-related (or Sequential) Organ Failure Assessment (SOFA) score [21] (Table 1) were employed to determine the initial severity of illness.
Table 1

Sepsis-related (or Sequential) Organ Failure Assessment (SOFA) scores

Parameter

SOFA score

 

0

1

2

3

4

Respiration (PaO2/FiO2 ratio)

>400

≤ 400

≤ 300

≤ 200 with respiratory support

≤ 100

Coagulation (platelets × 103/mm3

>150

≤ 150

≤ 100

≤ 50

≤ 20

Liver (bilirubin [mg/dl (μmol/l)])

<1.2 (<20)

1.2–1.9 (20–32)

2.0–5.9 (33–101)

6.0–11.9 (102–204)

>12.0 (>204)

Cardiovascular (hypotension)

No hypotension

MAP <70 mmHg

Dopamine ≤ 5 or dobutamine at any dose

Dopamine>5 or adrenaline (epinephrine) ≤ 0.1 noradrenaline (norepinephrine) ≤ 0.1

Dopamine >15 or adrenaline >0.1 noradrenaline >0.1

Central nervous system (GCS score)

15

19–14

10–12

6–9

<6

Renal (creatine [mg/dl] or urine output)

<1.2

1.2–1.9

2.0–3.4

3.5–4.9 or <500 ml/day

>5 or <200 ml/day

FiO2, fractional inspired oxygen; GCS, Glasgow Coma Scale; MAP, mean arterial pressure;

PaO2, arterial oxygen tension.

If required, patients underwent surgical procedures before the start of the study. No invasive surgery was performed during the 72-hour study period. All patients were ventilated in volume-controlled mode (Puritan Bennett 7200; Carlsbad, CA) and received continuous analgesic sedation with midazolam and fentanyl. Ventilator settings, level of positive end-expiratory pressure and fractional inspired oxygen were kept constant during intravenous administration of lornoxicam or placebo. Antibiotic treatment was adjusted according to the results of bacteriological culture, such as blood culture or culture of samples taken from different body sites. In all participants fluid replacement was administered to maintain central venous pressure between 4 and 8 mmHg. No inotropic agent was administered during the study. Those patients who met the criteria for severe sepsis presented above were enrolled in the study within 8 hours of intensive care unit (ICU) admission.

Protocol

Randomization was done using a computer-steered permuted block design. The study was planned prospective, randomized, double blind, and placebo controlled. In order to perform the study in a double-blind manner, drug solution was administered to all patients by a nurse who had no knowledge of the study protocol, and follow up was done by an anaesthetist who also had no knowledge of the study protocol. Twenty patients received lornoxicam 8 mg (Xefo; Abdi Ýbrahim, Istanbul, Turkey), administered intravenously every 12 hours for a total of six doses. In the placebo group, also including 20 patients, saline was administered using the same volume and dosing regimen.

Measurements

All patients had arterial catheters placed (Abbott Transpac® IV; Abbott, Sligo, Ireland) and central venous catheters placed via subclavian (Certofix trio V 720 7F×8"; Braun, Melsungen, Germany). Arterial blood samples were simultaneously withdrawn for measurements of pH, partial oxygen tension, partial carbon dioxide tension and arterial oxygen saturation (Medica Easy BloodGas; Massachusetts, USA). Central venous pressure, mean arterial pressure, heart rate and naso-opharyngeal temperature were continuously monitored (Space Labs Inc., Redmond, WA, USA). All measurements were obtained at baseline (before the start of the study) and again at 24, 48 and 72 hour after the start of infusion. Lactate, platelets, leucocytes, bilirubin, alanine aminotransferase and creatinine were determined at the same times (Vitalab Flexor, Dieren, The Netherlands).

TNF-α, IL-1β, IL-2 receptor, IL-6 and IL-8 levels were measured at the same times. Venous blood was collected into a 10 ml sterile plain tube (without anticoagulant) before administration of any medications and stored at -20°C. Before assay, all samples were thawed to room temperature and mixed by gentle swirling or inversion. All sera were assayed on the same day to avoid interassay variation. TNF-α, IL-1, IL-2 receptor, IL-6 and IL-8 levels were measured using a solid-phase, two-site chemiluminescent enzyme immunometric assay method (Immulite TNF-α, Immulite IL-1β, Immulite IL-2 receptor, IL-6 Immulite and IL-8 Immulite; EURO/DPC, Llanberis, UK). The antibodies used in this procedure have no known cross-reactivities with other cytokines. The intra-assay and interassay coefficients of variation, respectively, for this procedure were as follows: for IL-1β, 2.8–4.9% and 4.8–9.1%; for IL-2 receptor, 2.9–3.7% and 6.1–8.1%; for IL-6, 3.6–6.2% and 5.4–9.6%; for IL-8, 3.6–3.8% and 5.2–7.4%; and for TNF-α, 2.6–3.6% and 4.0–6.5%. The lowest detectable limits of IL-1β, IL-2 receptor, IL-6, IL-8 and TNF-α were 1.5 pg/ml, 5 U/ml, 5 pg/ml, 2 pg/ml and 1.7 pg/ml, respectively.

The duration of mechanical ventilation was recorded. Survival was defined as being alive at hospital discharge.

Statistical analysis

Repeated measures analysis of variance was used to evaluate the differences between and within groups from baseline. In the case of statistical significance, groups were tested by independent sample t-test to determine which difference was significant. Data are expressed as mean ± standard deviation. P < 0.05 was considered statistically significant.

Results

Patient characteristics

Clinical and demographic characteristics of the patients are listed in Table 2. Of the 40 patients included, 20 received intravenous lornoxicam and 20 received placebo. Fifteen patients had septic shock on admission (seven [35%] in the lornoxicam group and eight [40%] in the placebo group) and died while in the ICU. Baseline APACHE II scores (17.10 ± 3.58 and 18 ± 3.72 in the lornoxicam and placebo groups, respectively) and SOFA scores (5.90 ± 1.72 and 6.20 ± 2.2) were similar in the two groups (P > 0.05). SOFA scores at 24 hours (5.50 ± 1.52 and 6.1 ± 1.2 in the lornoxicam and placebo groups, respectively), 48 hours (5.60 ± 1.6 and 6.0 ± 1.3) and 72 hours (5.72 ± 1.4 and 6.1 ± 1.6) were also similar (P > 0.05). Infection was documented in all patients.
Table 2

Demographic and clinical characteristics of lornoxicam treated and placebo patients

Characteristic

Lornoxicam group (n = 20)

Placebo group (n = 20)

Age (years [range])

49 (19–87)

51 (20–89)

Sex (male/female)

13/7

9/11

Source of infection

  

Respiratory

15

17

Gastrointestinal

2

1

Blood

2

1

Urinary tract

1

1

APACHE II scorea

17.10 ± 3.58

18 ± 3.72

SOFA scorea

5.90 ± 1.72

6.20 ± 2.2

Duration of ventilationa

6.1 ± 2.4

5.8 ± 3.1

Length of staya

10.2 ± 7.1

9.2 ± 8.4

Mortality rate (%)

35

40

There were no significant differences between the groups. aValues are expressed as mean ± standard deviation. APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, Sepsis-related (or Sequential) Organ Failure Assessment.

Haemodynamic parameters and oxygen transport variables

There were no significant differences between groups with respect to pH, partial oxygen tension, partial carbon dioxide tension, arterial oxygen tension/inspired fractional oxygen ratio and arterial oxygen saturation (P > 0.05). No significant changes in mean arterial pressure and heart rate were found in either group (Table 3). There were no significant differences between groups in biochemical parameters (Table 4; P > 0.05).
Table 3

Haemodynamic, oxygen and temperature variables

Parameter

Baseline

Hours after the start of infusion

  

24

48

72

Heart rate (beats/min)

    

Lornoxicam

98 ± 24

99 ± 24

99 ± 22

96 ± 22

Placebo

95 ± 17

100 ± 23

98 ± 23

97 ± 22

Mean arterial pressure (mmHg)

    

Lornoxicam

91 ± 16

92 ± 13

89 ± 13

93 ± 13

Placebo

91 ± 18

93 ± 14

91 ± 12

89 ± 11

Arterial pH

    

Lornoxicam

7.34 ± 0.08

7.36 ± 0.07

7.33 ± 0.10

7.36 ± 0.06

Placebo

7.35 ± 0.07

7.37 ± 0.07

7.34 ± 0.07

7.37 ± 0.05

PaCO2 (torr)

    

Lornoxicam

34.8 ± 12.1

34.6 ± 11.8

35.00 ± 9.2

36.54 ± 11.1

Placebo

32.6 ± 10

33.5 ± 10.2

36.3 ± 10.13

34.33 ± 12

PaO2/FiO2 ratio (torr)

    

Lornoxicam

182 ± 68

186 ± 56

188 ± 64

189 ± 76

Placebo

184 ± 76

187 ± 45

181 ± 68

185 ± 68

SaO2 (%)

    

Lornoxicam

96.1 ± 3

96.1 ± 3.1

95.9 ± 3.8

95.9 ± 4.2

Placebo

96.9 ± 3.1

96.0 ± 3.2

96.0 ± 2.8

95.8 ± 3.9

Temperature (°C)

    

Lornoxicam

37.8 ± 0.75

37.2 ± 0.6

37.8 ± 0.5

37.9 ± 0.4

Placebo

37.6 ± 0.57

37.8 ± 0.4

37.6 ± 0.6

37.8 ± 0.5

No significant differences were found between groups. Data are expressed as mean ± standard deviation. FiO2, fractional oxygen tension; PaCO2, arterial carbon dioxide tension; PaO2, arterial oxygen tension; SaO2, arterial oxygen saturation.

Table 4

Biochemical parameters

Parameter

Baseline

Hours after the start of infusion

  

24

48

72

Lactate (mg/dl)

    

Lornoxicam

25.2 ± 4.1

25.0 ± 3.9

25.9 ± 5.2

26.2 ± 3.7

Placebo

26.3 ± 3.8

26.7 ± 2.9

27.0 ± 3.1

26.9 ± 4.8

Platelets (×109/l)

    

Lornoxicam

192.9 ± 16.5

193.5 ± 15.0

178.1 ± 15.4

182.9 ± 15.6

Placebo

188.5 ± 14.4

190.8 ± 15.1

188.7 ± 13.3

190.5 ± 16.7

Leucocytes (×109/l)

    

Lornoxicam

14 ± 8.3

15.8 ± 8.3

16.0 ± 7.8

15.9 ± 6.2

Placebo

13.5 ± 6.6

14.7 ± 4.7

15.7 ± 6.7

14.8 ± 7.4

Bilirubin (mg/dl)

    

Lornoxicam

0.89 ± 0.38

0.90 ± 0.45

0.93 ± 0.33

0.90 ± 0.34

Placebo

0.90 ± 0.62

0.91 ± 0.38

0.92 ± 0.28

0.91 ± 0.36

Alanine aminotransferase (IU/l)

    

Lornoxicam

35.4 ± 5.5

36.0 ± 10.8

35.1 ± 8.6

36.7 ± 8.4

Placebo

35.4 ± 7.4

35.5 ± 5.2

36.2 ± 6.0

37.4 ± 4.9

Creatinine (mg/dl)

    

Lornoxicam

1.13 ± 0.96

1.15 ± 0.85

1.2 ± 0.3

1.28 ± 0.8

Placebo

1.01 ± 0.91

1.1 ± 0.65

1.08 ± 0.7

1.1 ± 0.8

No significant differences were found between groups. Data are expressed as mean ± standard deviation.

Outcomes

Outcomes are listed in Table 2. In the ICU, the overall mortality rates were 35% (seven patients out of 20) in the lornoxicam group and 40% (eight patients out of 20) in the placebo group (P > 0.05). All of those who died did so while they were being mechanically ventilated. In the lornoxicam and placebo groups the mean durations of ventilation were 6.1 ± 2.4 and 5.8 ± 3.1 days, respectively (P > 0.05). The length of ICU stay in lornoxicam treated survivors was not significantly different from that of placebo treated survivors (10.2 ± 7.1 versus 9.2 ± 8.4 days; P > 0.05).

Plasma cytokine levels

TNF-α, IL-1β, IL-2 receptor, IL-6 and IL-8 levels remained unchanged during the study (Table 5).
Table 5

Cytokine levels

Cytokine

Baseline

Hours after the start of infusion

  

24

48

72

TNF-α (pg/ml)

    

Lornoxicam

25.7 ± 15

27.4 ± 16

26.68 ± 12.9

28.1 ± 16.8

Placebo

24.6 ± 18

25.4 ± 16.9

25.55 ± 11.8

26.3 ± 14.2

Il-1β (pg/ml)

    

Lornoxicam

6.4 ± 3.8

6.48 ± 6.07

6.21 ± 3.26

6.57 ± 1.8

Placebo

6.35 ± 1.4

6.2 ± 4.30

6.34 ± 4.2

6.19 ± 2.7

IL-2 receptor (U/ml)

    

Lornoxicam

1950 ± 1266

1890 ± 1150

1929 ± 1027

2050 ± 1100

Placebo

2270 ± 1110

2179 ± 1005

2300 ± 1190

2268 ± 1000

IL-6 (pg/ml)

    

Lornoxicam

100.6 ± 58

105.2 ± 54

108.5 ± 47

104.8 ± 38

Placebo

114.5 ± 385

115.6 ± 48

113.6 ± 51

116 ± 28

IL-8 (pg/ml)

    

Lornoxicam

171.50 ± 35

171.6 ± 19.3

172.1 ± 12.6

168.9 ± 11.3

Placebo

169.55 ± 27

168.3 ± 18.4

169.8 ± 18.2

171.0 ± 18.2

No significant differences were found between groups. Data are expressed as mean ± standard deviation. IL, interleukin; TNF, tumour necrosis factor.

Side effects

Intravenous lornoxicam was well tolerated by all patients, and no side effects were noted during or after administration of lornoxicam.

Discussion

Systemic inflammatory response leading to postoperative organ dysfunction and sepsis remains a formidable clinical challenge and carries a significant risk for mortality. Sepsis and septic shock remain major causes of death in ICUs. A number of studies have examined the role of nonselective COX inhibitors both in animal models of sepsis and in patients with sepsis syndrome. Several studies [1012] demonstrated beneficial effects of nonselective COX inhibition, predominantly in endotoxin-treated animals. However, subsequent studies [22, 23] examining the role played by NSAIDs, particularly ibuprofen, in human sepsis trials have been disappointing. The present study was therefore conducted to determine whether COX inhibition is upregulated early after the onset of severe sepsis, and if so whether COX inhibition prevents the occurrence of septic shock.

The arachidonic acid pathway is highly activated in macrophages, monocytes and other inflammatory cells, resulting in the formation of eicosonoids. PGs are involved in all phases of the inflammatory process, including fever and pain reactions, as well as in a large number of physiological functions, including intestinal motility, platelet aggregation, vascular tone, renal function and gastric secretion, among others. Two COX isoforms have been identified: COX-1 and COX-2. The former is a constitutive enzyme that is expressed in many cells as a house-keeping enzyme and stimulates homeostatic production of PGs. COX-2 is an inducible form of the enzyme that is expressed at the onset of inflammation by many cell types that are involved in the inflammatory response. NSAIDs act mainly through COX inhibitors, thus preventing the formation of proinflammatory prostanoids. Lornoxicam, a new member of the oxicam class of NSAIDs, inhibits PG synthesis via inhibition of COX, but it does not inhibit 5-lipoxygenase. Lornoxicam is at least 10 times more potent as an anti-inflammatory agent than piroxicam, and 12 times more potent as an analgesic than tenoxicam [17, 19].

The primary pharmacological action of NSAIDs is, of course, to decrease the formation of PGs and thromboxanes by inhibiting COX, a key enzyme in the biochemical pathway that leads to formation of these potent mediators [24]. Accordingly, products of the COX pathway, sometimes referred to as 'prostanoids', have been implicated in the pathogenesis of the deleterious systemic consequences of serious infection and/or endotoxaemia. In addition, the toxic effects of TNF (thought to be one of the primary cytokines responsible for LPS-induced lethality) can be ameliorated by treating mice or rats with NSAIDs such as indomethacin or ibuprofen [25]. NSAIDs have been shown to increase release cytokines (TNF, IL-6, or IL-8) by stimulated mononuclear cells in vitro [26, 27].

Complications of sepsis have been related to an intense host response based on a delicate equilibrium between various proinflammatory and anti-inflammatory mediators [28]. Overwhelming production of proinflammatory cytokines, such as TNF-α, IL-1β, IL-2 receptor, IL-6 and IL-8, may induce biochemical and cellular alterations either directly or by orchestrating secondary inflammatory pathways.

Reddyl and coworkers [5] evaluated the effect of pretreatment with NS-398, a highly selective COX-2 inhibitor, on survival and inflammatory mediator production in two models of sepsis in mice (LPS challenge and peritonitis induced by caecal ligation and puncture [CLP]). They found that selective inhibition of COX-2 resulted in improvement in early survival in murine endotoxaemia but not in a more physiologically relevant model of abdominal sepsis (CLP). The early improvement in survival in endotoxin-challenged animals was not attributable to changes in inflammatory cytokine expression or organ-specific neutrophil sequestration. Pretreatment with NS-398 failed to improve long-term survival in either of the models studied, although in the endotoxaemia model administration of the COX-2 inhibitor had a modest salutary effect on early mortality. In addition, although treatment with NS-398 blocked LPS-induced increases in the circulating levels of immunoreactive PGE2, injection of the COX-2 inhibitor did not modulate plasma concentrations of TNF or the CXC chemokine KC.

Knoferl and coworkers [29] also evaluated the effect of pretreatment with NS-398, that trauma/haemorrhage results in activation of Kupffer cells to release inflammatory mediators and it leads to immunosuppression. In vitro production of IL-6 by Kupffer cells after CLP was significantly reduced by in vivo NS-398 treatment. However, NS-398 had no effect on TNF-α levels in vivo or in vitro. Strong and coworkers [12] showed that administration of NS-398 for 24 hours after trauma improved survival when mice were subjected to CLP and puncture 7 days later. It is noteworthy that NS-398 exhibited protective effects in two models of sepsis characterized by infection in the setting of trauma-induced immunosuppression, whereas the drug was largely ineffective when sepsis was induced in immunocompetent animals. Dallal and coworkers [30] demonstrated that T-cell suppression during neonatal sepsis is accompanied by a decrease in IL-2 production. Such suppression was ameliorated by COX-2 inhibitor, suggesting a role for PGE2 in suppressed T-cell-mediated immune function in neonatal sepsis. Arons and colleagues [22] compared the clinical and physiological characteristics of febrile septic patients with those of hypothermic septic patients, and compared plasma levels of cytokines TNF-α and IL-6 and thromboxane B2 and prostacyclin between hypothermic septic patients and febrile patients. They administered ibuprofen but found that this drug had no effect on cytokine levels.

Reddyl and coworkers [5] indicated that pharmacological inhibition of COX-2 has only very modest effects on outcome in experimental sepsis or endotoxaemia. Because these findings are discrepant with respect to those obtained with isoform nonselective agents, it is regrettable that those investigators did not include a 'positive control' arm in their studies to evaluate the effects of treatment with an agent such as indomethacin or ibuprofen in their laboratory's models of sepsis. In our study we did not observe any significant changes in systemic cytokine levels during NSAID administration in humans with severe sepsis. Cytokine levels in plasma do not necessarily reflect local synthesis of cytokines by cells. Many cells have surface receptors for these cytokines with high binding properties, and target cells and soluble receptors trap cytokines. Thus, cytokines released at the local level may remain undetected in plasma. In the present study we found plasma cytokine levels to remain unchanged over a period of 72 hours.

Wang and coworkers [31] conducted a study to determine whether inhibition of PGI2 synthesis prevents the hyperdynamic response in early sepsis in animals. Those investigators found that inhibition of PGI2 production did not prevent the hyperdynamic and hypercardiovascular responses during early sepsis; hence, mediators other than PGI2 appear to play a major role in producing the hyperdynamic response under such conditions. Fox and colleagues [32] postulated that the attenuated pulmonary and systemic vascular contractility observed in sepsis was secondary to the release of vasodilator PGs. They used the COX inhibitor meclofenamate to inhibit PG synthesis in a model of hyperdynamic sepsis, and found that meclofenamate had no effect on either the pulmonary or systemic response to phenylephrine infusion in septic animals. However, Wanecek and coworkers [11] demonstrated that endotoxin-induced pulmonary hypertension in the pig can be prevented with a combination of the nonpeptide mixed endothelin receptor antagonist bosentan and the COX inhibitor diclofenac. They found that the combination of bosentan and diclofenac induced systemic and pulmonary vasodilatation. During endotoxin shock, this drug combination efficiently counteracted pulmonary hypertension and improved cardiac performance, and splenic and renal blood flows. These favourable circulatory effects might have resulted in a reduction in both sympathetic nervous system activation and metabolic acidosis. In the present study we found that lornoxicam had no effect on the cardiovascular and pulmonary systems in severe sepsis in humans, but our study was designed to assess the effects of lornoxicam treatment given before septic shock but after systemic inflammatory response syndrome. For this reason we identified no serious cardiovascular and pulmonary system problems in the patients studied.

Arons and coworkers [22] compared clinical and physiological characteristics of febrile septic patients with those in hypothermic septic patients, and compared plasma levels of cytokines TNF-α and IL-6, and thomboxane B2 and prostacyclin between hypothermic septic patients and febrile patients. Those investigators found that ibuprofen treatment had a positive impact on vital signs, organ failure and mortality in hypothermic septic patients, and concluded that ibuprofen could substantially decrease mortality in this selected group of septic patients. In our study we found that lornoxicam had no effect on vital signs and mortality in patients with severe sepsis. The overall ICU mortality rate was 37.5% (15 patients out of 40) in total, and these deaths were all attributable to septic shock. However, all of the patients died after completion of the study.

Lornoxicam has been shown to produce less gastric toxicity than its nonselective counterparts. This may be especially important in critically ill patients, who are at significantly greater risk for developing gastric ulceration. In addition, the lack of inhibitory effect on platelet function, which occurs with the use of COX-2 selective compounds, may decrease the incidence of bleeding complications [17, 19]. In the present study we did not identify any lornoxicam related adverse effects.

In summary, we found that intravenous lornoxicam had no effect on haemodynamic and biochemical parameters, cytokine levels, or patient outcomes in severe sepsis. Selective inhibition of COX-2 in sepsis requires further study. However, the findings reported here, indicating that lornoxicam lacks benefit in patients with severe sepsis, are disappointing.

Key messages

  • Administration of intravenous lornoxicam appeared to confer no benefit in patients with severe sepsis.

Abbreviations

APACHE: 

Acute Physiology and Chronic Health Evaluation

CLP: 

caecal ligation and puncture

COX: 

cyclo-oxygenase

ICU: 

intensive care unit

IL: 

interleukin

LPS: 

lipopolysaccharide

NSAID: 

nonsteroidal anti-infllammatory drug

PG: 

prostaglandin

SOFA: 

Sepsis-related (Sequential) Organ Failure Assessment

TNF: 

tumour necrosis factor.

Declarations

Authors’ Affiliations

(1)
Associate Professor, Department of Anaesthesiology and Reanimation, Medical Faculty, Trakya University
(2)
Department of Anaesthesiology, Professor,Reanimation,Trakya University

References

  1. Bone RC: Gram-negative sepsis: a dilemma of modern medicine. Clin Microbiol Rev 1993, 6: 57-68.PubMed CentralPubMedGoogle Scholar
  2. Members of The American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee: American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992, 20: 864-874.View ArticleGoogle Scholar
  3. Bernard GR, Reines HD, Halushka PV, Higgins SB, Metz CA, Swindell BB, Wright PE, Watts FL, Vrbanac JJ: Prostacyclin and thromboxane A2 formation is increased in human sepsis syndrome: Effects of cyclooxygenase inhibition. Am Rev Respir Dis 1991, 144: 1095-1101.View ArticlePubMedGoogle Scholar
  4. Holtzman MJ: Arachadonic acid metabolism. Implications of biological chemistry for lung function and disease. Am Rev Respir Dis 1991, 143: 188-203.View ArticlePubMedGoogle Scholar
  5. Reddy RC, Chen GH, Tateda K, Tsai WC, Phare SM, Mancuso P, Peters-Golden M, Standiford TJ: Selective inhibition of COX-2 improves early survival in murine endotoxemia but not in bacterial peritonitis. Am J Physiol Lung Cell Mol Physiol 2001, 281: L537-L543.PubMedGoogle Scholar
  6. Strassmann G, Patil-Koota V, Finkelman F, Fong M, Kambayashi T: Evidence for the involvement of interleukin 10 in the differential deactivation of murine peritoneal macrophages by prostaglandin E2. J Exp Med 1994, 180: 2365-2370. 10.1084/jem.180.6.2365View ArticlePubMedGoogle Scholar
  7. van der Pouw Kraan TC, Boeije LC, Smeenk RJ, Wijdenes J, Aarden LA: Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J Exp Med 1995, 181: 775-779. 10.1084/jem.181.2.775View ArticlePubMedGoogle Scholar
  8. Portanova JP, Zhang Y, Anderson GD, Hauser SD, Masferrer JL, Seibert K, Gregory SA, Isakson PC: Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. J Exp Med 1996, 184: 883-891. 10.1084/jem.184.3.883View ArticlePubMedGoogle Scholar
  9. Lipsky PE: Specific COX-2 inhibitors in arthritis, oncology, and beyond: where is the science headed? J Rheumatol Suppl 1999, 56: 25-30.PubMedGoogle Scholar
  10. Beamer KC, Daly T, Vargish T: Hemodynamic evaluation of ibuprofen in canine hypovolemic shock. Circ Shock 1987, 23: 51-57.PubMedGoogle Scholar
  11. Wanecek M, Rudehill A, Hemsen A, Lundberg JM, Weitzberg E: The endothelin receptor antagonist, bosentan, in combination with the cyclooxygenase inhibitor, diclofenac, counteracts pulmonary hypertension in porcine endotoxin shock. Crit Care Med 1997, 25: 848-857. 10.1097/00003246-199705000-00022View ArticlePubMedGoogle Scholar
  12. Strong VE, Mackrell PJ, Concannon EM, Naama HA, Schaefer PA, Shaftan GW, Stapleton PP, Daly JM: Blocking prostaglandin E2 after trauma attenuates pro-inflammatory cytokines and improves survival. Shock 2000, 14: 374-379.View ArticlePubMedGoogle Scholar
  13. Crofford LJ, Lipsky PE, Brooks P, Abramson SB, Simon LS, van de Putte LB: Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum 2000, 43: 4-13. 10.1002/1529-0131(200001)43:1<4::AID-ANR2>3.0.CO;2-VView ArticlePubMedGoogle Scholar
  14. Lipsky PE, Isakson PC: Outcome of specific COX-2 inhibition in rheumatoid arthritis. J Rheumatol Suppl 1997, 49: 9-14.PubMedGoogle Scholar
  15. Shoup M, He LK, Liu H, Shankar R, Gamelli R: Cyclooxygenase-2 inhibitor NS-398 improves survival and restores leukocyte counts in burn infection. J Trauma 1998, 45: 215-220.View ArticlePubMedGoogle Scholar
  16. Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, Isakson PC, Geis GS: Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998, 41: 1591-1602. 10.1002/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-JView ArticlePubMedGoogle Scholar
  17. Balfour JA, Fitton A, Barradell LB: Lornoxicam: a review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Drugs 1996, 51: 639-657.View ArticlePubMedGoogle Scholar
  18. Berg J, Fellier H, Christoph T, Grarup J, Stimmeder D: The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res 1999, 48: 369-379. 10.1007/s000110050474View ArticlePubMedGoogle Scholar
  19. Radhofer-Welte S, Rabasseda X: Lornoxicam, a new potent NSAID with an improved tolerability profile. Drugs Today (Barc) 2000, 36: 55-76.View ArticleGoogle Scholar
  20. Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of disease classification system. Crit Care Med 1985, 13: 818-829.View ArticlePubMedGoogle Scholar
  21. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG: The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. Intensive Care Med 1996, 22: 707-710. 10.1007/s001340050156View ArticlePubMedGoogle Scholar
  22. Arons MM, Wheeler AP, Bernard GR, Christman BW, Russell JA, Schein R, Summer WR, Steinberg KP, Fulkerson W, Wright P, et al.: Effects of ibuprofen on the physiology and survival of hypothermic sepsis. Crit Care Med 1999, 27: 699-707. 10.1097/00003246-199904000-00020View ArticlePubMedGoogle Scholar
  23. Bernard GR, Wheeler AP, Russell JA, Schein R, Summer WR, Steinberg KP, Fulkerson WJ, Wright PE, Christman BW, Dupont WD, et al.: The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 1997, 336: 912-918. 10.1056/NEJM199703273361303View ArticlePubMedGoogle Scholar
  24. Fink MP: Prostaglandins and sepsis: still a fascinating topic despite almost 40 years of research. Am J Physiol Lung Cell Mol Physiol 2001, 281: L534-L536.PubMedGoogle Scholar
  25. Fletcher JR, Collins JN, Graves III ED, Luterman A, Williams MD, Izenberg SD, Rodning CB: Tumor necrosis factor-induced mortality is reversed with cyclooxygenase inhibition. Ann Surg 1993, 217: 668-674.PubMed CentralView ArticlePubMedGoogle Scholar
  26. Marsh CB, Wewers MD: The pathogenesis of sepsis: factors that modulate the response to gram-negative bacterial infection. Clin Chest Med 1996, 17: 183-197.View ArticlePubMedGoogle Scholar
  27. Dong YL, Herndon DN, Yan TZ, Waymack JP: Blockade of prostaglandin products augments macrophage and neutrophil tumor necrosis factor synthesis in burn injury. J Surg Res 1993, 54: 480-485. 10.1006/jsre.1993.1074View ArticlePubMedGoogle Scholar
  28. Ertel W, Morrison MH, Wang P, Ba ZF, Ayala A, Chaudry IH: The complex pattern of cytokines in sepsis. Association between prostaglandins, cachectin, and interleukins. Ann Surg 1991, 214: 141-148.PubMed CentralView ArticlePubMedGoogle Scholar
  29. Knoferl MW, Diodato MD, Schwacha MG, Cioffi WG, Bland KI, Chaudry IH: Cyclooxygenase-2-mediated regulation of Kupffer cell interleukin-6 production following trauma-hemorrhage and subsequent sepsis. Shock 2001, 16: 479-483.View ArticlePubMedGoogle Scholar
  30. Dallal O, Ravindranath TM, Choudhry MA, Kohn A, Muraskas JK, Namak SY, Alattar MH, Sayeed MM: T-cell proliferative responses following sepsis in neonatal rats. Biol Neonate 2003, 83: 201-207. 10.1159/000068921View ArticlePubMedGoogle Scholar
  31. Wang P, Zhou M, Cioffi WG, Bland KI, Ba ZF, Chaudry IH: Is prostacyclin responsible for producing the hyperdynamic response during early sepsis? Crit Care Med 2000, 28: 1534-1539. 10.1097/00003246-200005000-00046View ArticlePubMedGoogle Scholar
  32. Fox GA, Paterson NA, McCormack DG: Cyclooxygenase inhibition and vascular reactivity in a rat model of hyperdynamic sepsis. J Cardiovasc Pharmacol 1996, 28: 30-35. 10.1097/00005344-199607000-00006View ArticlePubMedGoogle Scholar

Copyright

© Memiş et al., licensee BioMed Central Ltd. 2004

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is cited.

Advertisement